Foghorn Therapeutics Inc. (FHTX)

Market Cap	189.55M
Revenue (ttm)	32.57M
Net Income (ttm)	-103.21M
Shares Out	42.22M
EPS (ttm)	-2.46
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	85,140
Open	4.15
Previous Close	4.25
Day's Range	4.14 - 4.52
52-Week Range	2.84 - 9.97
Beta	2.48
Analysts	Strong Buy
Price Target	14.67 (+226.73%)
Earnings Date	Nov 2, 2023

About FHTX

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodyspl...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 23, 2020
• Employees: 161
• Stock Exchange: NASDAQ
• Ticker Symbol: FHTX

Financial Performance

In 2022, FHTX's revenue was $19.23 million, an increase of 1357.77% compared to the previous year's $1.32 million. Losses were -$108.88 million, 7.46% more than in 2021.

Analyst Forecast

According to 6 analysts, the average rating for FHTX stock is "Strong Buy." The 12-month stock price forecast is $14.67, which is an increase of 226.73% from the latest price.

Price Target

$14.67

(226.73% upside)

Analyst Consensus: Strong Buy